NICE risks rifts with further refusals to recommend drugs

15 February 2017

Days after receiving a backlash from a pharma company for its decision not to recommend a new treatment for a certain patient group, the National Institute for Care and Excellence (NICE) has again shown that it will take a stance against drugs which it does not judge to be cost-effective.

NICE, the medicines cost-effectiveness watchdog for England and Wales, has not recommended Kanuma (sebelipase alfa) for infants, children and adults with lysosomal acid lipase deficiency (LAL-D) in a final evaluation document (FED) published on Wednesday.

"Once again, the UK lags behind other countries in funding medicines for rare and ultra-rare diseases with limited treatment options"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK